TUCSON,
Ariz., Dec. 19, 2022 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company
has submitted a 510(k) application to the FDA for Gram-negative
menu expansion and breakpoint updates for the Accelerate
PhenoTest® BC kit. Included in the submission are
additional escalation and de-escalation agents for Gram-negative
organisms, additional antibiotics for Acinetobacter
baumannii, and breakpoint updates. These updates add oral
de-escalation antibiotic options for clinicians to use, which can
assist with expediting patient discharge plans.

Jack Phillips, Chief Executive
Officer of Accelerate Diagnostics, stated, "We are very excited to
offer this updated PhenoTest panel, which adds meaningful new
antibiotic choices for clinicians to minimize time to optimal
therapy for patients with bloodstream infections. These additions
and improvements will increase the value of the Pheno system in
hospitals across the country, enhancing the clinical value labs
have been experiencing for the past several years. We continue to
innovate to provide laboratories with lifesaving technology for
patients with serious infections."
About Accelerate Diagnostics,
Inc.
Accelerate Diagnostics, Inc. is an in
vitro diagnostics company dedicated to providing solutions
for the global challenges of antibiotic resistance and sepsis. The
Accelerate Pheno® system and Accelerate
PhenoTest® BC kit combine several technologies aimed at
reducing the time clinicians must wait to determine the most
optimal antibiotic therapy for deadly infections. The FDA cleared
system and kit fully automate the sample preparation steps to
report phenotypic antibiotic susceptibility results in
approximately 7 hours direct from positive blood cultures. Recent
external studies indicate the solution offers results 1–2 days
faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient
days earlier.
"Accelerate Diagnostics" and diamond shaped logos and marks are
registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
Forward-Looking
Statements
Certain of the statements made in this press release are forward
looking or may have forward looking implications. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Information about the risks
and uncertainties faced by Accelerate Diagnostics is contained in
the section captioned "Risk Factors" in the company's most recent
Annual Report on Form 10-K, filed with the Securities and Exchange
Commission on March 14, 2022, and in any other reports that
the company files with the Securities and Exchange Commission. The
company's forward-looking statements could be affected by general
industry and market conditions, and regulatory approvals. Except as
required by federal securities laws, the company undertakes no
obligation to update or revise these forward-looking statements to
reflect new events, uncertainties or other contingencies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-submits-510k-application-to-fda-for-gram-negative-menu-expansion-and-breakpoint-updates-for-the-accelerate-phenotest-bc-kit-301706393.html
SOURCE Accelerate Diagnostics, Inc.